business
Autolus Therapeutics Q1 Earnings Call Highlights
Key takeaways
- Autolus Therapeutics Q1 Earnings Call Highlights Market Beat Thu, May 14, 2026 at 9:07 PM GMT+7 6 min read AUTL Key Points Interested in Autolus Therapeutics PLC Sponsored ADR?
- Autolus Therapeutics said first-quarter 2026 product revenue rose to $26.2 million, driven by early traction for AUCATZYL in the U.S.
- The company reported a positive gross margin for the quarter and expects manufacturing efficiency gains to support further improvement, targeting a 65% to 70% gross profit margin in its peak adult ALL business.
Autolus Therapeutics Q1 Earnings Call Highlights Market Beat Thu, May 14, 2026 at 9:07 PM GMT+7 6 min read AUTL Key Points Interested in Autolus Therapeutics PLC Sponsored ADR? Here are five stocks we like better.
Autolus Therapeutics said first-quarter 2026 product revenue rose to $26.2 million, driven by early traction for AUCATZYL in the U.S. and U.K., and it reaffirmed full-year revenue guidance of $120 million to $135 million.
The company reported a positive gross margin for the quarter and expects manufacturing efficiency gains to support further improvement, targeting a 65% to 70% gross profit margin in its peak adult ALL business.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
Earnings call transcript: Cellebrite Q1 2026 earnings beat estimates
Investing.com
Earnings call transcript: WhiteFiber Q1 2026 sees significant EPS miss
Investing.com
Earnings call transcript: CSN Mineração Q1 2026 shows mixed results
Investing.com
Earnings call transcript: Bitdeer Technologies Q1 2026 earnings miss forecasts
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop